BHIC (BioScience Health Innovations) Piotroski F-Score: 2 (As of Jun. 26, 2026) — 50% Below Median


BHIC BioScience Health Innovations Inc BHIC
45 GF Score
Price $4.35
GF Value $164.84
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is BioScience Health Innovations Piotroski F-Score?

BioScience Health Innovations BHIC 45 Piotroski F-Score is 2 as of Jun. 26, 2026, which is 50% below its 10-year median of 4.00. GuruFocus rates BHIC with a GF Score™ of 45/100 and a GF Value™ of $164.84 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 652 Healthcare Providers & Services companies, BioScience Health Innovations ranks worse than 92.94% on this metric.

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

BioScience Health Innovations has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for BioScience Health Innovations's Piotroski F-Score or its related term are showing as below:

BHIC' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 5
Current: 2

During the past 7 years, the highest Piotroski F-Score of BioScience Health Innovations was 5. The lowest was 2. And the median was 4.

BioScience Health Innovations  (OTCPK:BHIC) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


BioScience Health Innovations Piotroski F-Score Related Terms


BioScience Health Innovations Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for BioScience Health Innovations's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioScience Health Innovations Piotroski F-Score Chart

BioScience Health Innovations Annual Data
Trend Aug19 Aug20 Aug21 Aug22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial 3.00 3.00 3.00 5.00 3.00

BioScience Health Innovations Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 4.00 3.00 2.00

BHIC vs PETS, SHFH, SCNX: Piotroski F-Score Comparison

For the Pharmaceutical Retailers subindustry, BioScience Health Innovations's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioScience Health Innovations Piotroski F-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, BioScience Health Innovations's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where BioScience Health Innovations's Piotroski F-Score falls into.


BHIC
45GF Score
BioScience Health Innovations Inc BHIC
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 0.458 + -0.009 + -0.234 + -0.23 = $-0.02 Mil.
Cash Flow from Operations was 0.285 + -0.34 + -0.101 + -0.552 = $-0.71 Mil.
Revenue was 1.757 + 1.131 + 1.573 + 0.751 = $5.21 Mil.
Gross Profit was 1.074 + 0.698 + 0.572 + 0.486 = $2.83 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(1.395 + 2.057 + 2.067 + 1.707 + 2.33) / 5 = $1.9112 Mil.
Total Assets at the begining of this year (Mar25) was $1.40 Mil.
Long-Term Debt & Capital Lease Obligation was $0.46 Mil.
Total Current Assets was $2.20 Mil.
Total Current Liabilities was $0.19 Mil.
Net Income was 0.074 + 0.056 + 0.01 + 0.427 = $0.57 Mil.

Revenue was 0.384 + 0.573 + 0.61 + 1.227 = $2.79 Mil.
Gross Profit was 0.31 + 0.425 + 0.339 + 0.896 = $1.97 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(0.155 + 0.214 + 0.416 + 0.874 + 1.395) / 5 = $0.6108 Mil.
Total Assets at the begining of last year (Mar24) was $0.16 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $1.34 Mil.
Total Current Liabilities was $0.13 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

BioScience Health Innovations's current Net Income (TTM) was -0.02. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

BioScience Health Innovations's current Cash Flow from Operations (TTM) was -0.71. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-0.015/1.395
=-0.01075269

ROA (Last Year)=Net Income/Total Assets (Mar24)
=0.567/0.155
=3.65806452

BioScience Health Innovations's return on assets of this year was -0.01075269. BioScience Health Innovations's return on assets of last year was 3.65806452. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

BioScience Health Innovations's current Net Income (TTM) was -0.02. BioScience Health Innovations's current Cash Flow from Operations (TTM) was -0.71. ==> -0.71 <= -0.02 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0.46/1.9112
=0.24068648

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/0.6108
=0

BioScience Health Innovations's gearing of this year was 0.24068648. BioScience Health Innovations's gearing of last year was 0. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=2.195/0.185
=11.86486486

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=1.339/0.133
=10.06766917

BioScience Health Innovations's current ratio of this year was 11.86486486. BioScience Health Innovations's current ratio of last year was 10.06766917. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

BioScience Health Innovations's number of shares in issue this year was 11.377. BioScience Health Innovations's number of shares in issue last year was 44.336. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2.83/5.212
=0.54297774

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1.97/2.794
=0.70508232

BioScience Health Innovations's gross margin of this year was 0.54297774. BioScience Health Innovations's gross margin of last year was 0.70508232. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=5.212/1.395
=3.73620072

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=2.794/0.155
=18.02580645

BioScience Health Innovations's asset turnover of this year was 3.73620072. BioScience Health Innovations's asset turnover of last year was 18.02580645. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+0+0+1+1+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

BioScience Health Innovations has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 2 mean?
BioScience Health Innovations (BHIC) has a Piotroski F-Score of 2 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on BioScience Health Innovations and its competitors. This is 50% below median its historical median of 4.00. Over the past decade, BioScience Health Innovations' Piotroski F-Score has ranged from 2.00 to 5.00. According to the industry distribution chart, BioScience Health Innovations ranks #606 out of 652 companies in the Healthcare Providers & Services industry, placing it in the top 92.9%.
Is BioScience Health Innovations' Piotroski F-Score too high?
BioScience Health Innovations' current Piotroski F-Score of 2 is 50% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 5.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. BioScience Health Innovations' value of 2 is 60% below this industry median. Based on the distribution chart, BioScience Health Innovations ranks #606 out of 652 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, BioScience Health Innovations has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioScience Health Innovations' Piotroski F-Score compare to PETS and SHFH?
According to the Healthcare Providers & Services industry distribution chart, BioScience Health Innovations ranks #606 out of 652 companies for Piotroski F-Score. This places BioScience Health Innovations in the lower half of its industry. The industry median Piotroski F-Score is 5.00. BioScience Health Innovations' value of 2 is 60% below this benchmark. Historically, BioScience Health Innovations' own Piotroski F-Score has ranged from 2.00 to 5.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, BioScience Health Innovations has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 652 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioScience Health Innovations's current Piotroski F-Score of 2 is 60% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on BioScience Health Innovations and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioScience Health Innovations's current Piotroski F-Score is 2, which is 50% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioScience Health Innovations stock overvalued right now?
Based on GuruFocus' analysis, BioScience Health Innovations (BHIC) is currently considered Possible Value Trap. The stock's GF Value™ is $164.84, compared to a current price of $4.35 — trading 97.4% below its estimated fair value. The current Piotroski F-Score is 2, which is 50% below median its 10-year median of 4.00 and 60% below the Healthcare Providers & Services industry median of 5.00. BioScience Health Innovations' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For BioScience Health Innovations (BHIC), the current Piotroski F-Score is 2 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioScience Health Innovations (BHIC) Overvalued in 2026?

Based on GuruFocus' analysis, BioScience Health Innovations stock appears to be undervalued. The current stock price of $4.35 is trading 97.4% below its estimated GF Value™ of $164.84. GuruFocus considers BioScience Health Innovations to be Possible Value Trap.

Key valuation signals for BHIC:

  • Piotroski F-Score: 2 (50% below median its 10-year median of 4.00)
  • GF Value™: $164.84 vs. price of $4.35 (97.4% below fair value)
  • GF Score™: 45/100 with 5 warning signs
  • Industry Position: 60% below the Healthcare Providers & Services median (#606 of 652)

No single metric tells the full story. See the BHIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioScience Health Innovations Business Description

Address 14857 South Concord Park Drive, Bluffdale, UT, USA, 84065
BioScience Health Innovations Inc is engaged in full-scale operations as a distributor and generates revenue. The company's main business is to sell clinically tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and various other distribution channels. The company develops, manufactures, and distributes science-backed nutritional supplements and delivery systems targeting cellular health, mitochondrial optimization, hormonal balance, and longevity.
45GF Score

Get the complete analysis for BHIC

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.35
Price
$164.84
GF Value